Drugging the undruggable: early phase trial shows trabectedin and low-dose irinotecan downregulate EWSR1::FLI1 and has clinical activity in advanced Ewing sarcoma
- DOI
- 10.1016/j.trecan.2026.07.010
- Published
- 2026-08
- Container
- Trends in Cancer
- Publisher
- Elsevier BV
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1016/j.trecan.2026.07.010,
title = {Drugging the undruggable: early phase trial shows trabectedin and low-dose irinotecan downregulate EWSR1::FLI1 and has clinical activity in advanced Ewing sarcoma},
author = {David S. Shulman and Katherine A. Janeway},
year = {2026},
journal = {Trends in Cancer},
doi = {10.1016/j.trecan.2026.07.010},
url = {https://doi.org/10.1016/j.trecan.2026.07.010}
}RIS
TY - JOUR TI - Drugging the undruggable: early phase trial shows trabectedin and low-dose irinotecan downregulate EWSR1::FLI1 and has clinical activity in advanced Ewing sarcoma AU - David S. Shulman AU - Katherine A. Janeway PY - 2026 JO - Trends in Cancer DO - 10.1016/j.trecan.2026.07.010 UR - https://doi.org/10.1016/j.trecan.2026.07.010 ER -
APA
Shulman, D. S., & Janeway, K. A. (2026). Drugging the undruggable: early phase trial shows trabectedin and low-dose irinotecan downregulate EWSR1::FLI1 and has clinical activity in advanced Ewing sarcoma. Trends in Cancer. https://doi.org/10.1016/j.trecan.2026.07.010
Source records
- crossref · retrieved 2026-09-25T18:09:43.995Z